[go: up one dir, main page]

WO2008068621A3 - Combination product with ido inhibitor and tumor targeted ifn-gamma - Google Patents

Combination product with ido inhibitor and tumor targeted ifn-gamma Download PDF

Info

Publication number
WO2008068621A3
WO2008068621A3 PCT/IB2007/004299 IB2007004299W WO2008068621A3 WO 2008068621 A3 WO2008068621 A3 WO 2008068621A3 IB 2007004299 W IB2007004299 W IB 2007004299W WO 2008068621 A3 WO2008068621 A3 WO 2008068621A3
Authority
WO
WIPO (PCT)
Prior art keywords
gamma
combination product
ido inhibitor
tumor targeted
targeted ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/004299
Other languages
French (fr)
Other versions
WO2008068621A2 (en
Inventor
Angelo Corti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGC Biologics SpA
Original Assignee
MolMed SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MolMed SpA filed Critical MolMed SpA
Publication of WO2008068621A2 publication Critical patent/WO2008068621A2/en
Publication of WO2008068621A3 publication Critical patent/WO2008068621A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical product comprising, in combination, (i) an indoleamine 2,3- dioxygenase (IDO) inhibitor and (ii) a conjugation product of IFNγ and a targeting moiety (TM)or a polynucleotide encoding therefor.
PCT/IB2007/004299 2006-12-05 2007-12-05 Combination product with ido inhibitor and tumor targeted ifn-gamma Ceased WO2008068621A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0624308A GB0624308D0 (en) 2006-12-05 2006-12-05 Combination product
GB0624308.3 2006-12-05

Publications (2)

Publication Number Publication Date
WO2008068621A2 WO2008068621A2 (en) 2008-06-12
WO2008068621A3 true WO2008068621A3 (en) 2008-07-31

Family

ID=37711599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004299 Ceased WO2008068621A2 (en) 2006-12-05 2007-12-05 Combination product with ido inhibitor and tumor targeted ifn-gamma

Country Status (2)

Country Link
GB (1) GB0624308D0 (en)
WO (1) WO2008068621A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
KR101873672B1 (en) 2014-05-15 2018-07-02 아이테오스 테라퓨틱스 Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
CA2979616C (en) 2015-03-17 2020-04-28 Pfizer Inc. Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
TW201705955A (en) * 2015-05-14 2017-02-16 輝瑞大藥廠 Combination therapies comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-PD1/anti-PD-L1 antibody
KR20210089270A (en) 2015-07-16 2021-07-15 바이오카인 테라퓨틱스 리미티드 Compositions and methods for treating cancer
US10544095B2 (en) 2015-08-10 2020-01-28 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
JP2018532406A (en) * 2015-11-09 2018-11-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Screening assay to identify IDO1 and / or TDO modifiers
CN106075453A (en) * 2016-07-12 2016-11-09 中国医学科学院基础医学研究所 A kind of anti-tumor medicinal preparation combination
JP2021505151A (en) * 2017-12-08 2021-02-18 クロモセル コーポレイション Tryptophan derivative as a sweetener
EP3982756A1 (en) * 2019-06-12 2022-04-20 CORN Products Development Inc. Compositions with sugar like characteristics
EP3882257A1 (en) * 2020-03-20 2021-09-22 Ospedale San Raffaele S.r.l. Ngr conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067633A2 (en) * 2004-12-23 2006-06-29 Molmed Spa Conjugation product

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067633A2 (en) * 2004-12-23 2006-06-29 Molmed Spa Conjugation product

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADIKARI S B ET AL: "Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY NOV 2004, vol. 138, no. 2, November 2004 (2004-11-01), pages 230 - 236, XP002481684, ISSN: 0009-9104 *
BRANDACHER G ET AL: "Antitumoral activity of interferon-[gamma] involved in impaired immune function in cancer patients", CURRENT DRUG METABOLISM 200608 NL, vol. 7, no. 6, August 2006 (2006-08-01), pages 599 - 612, XP009100735, ISSN: 1389-2002 *
CURNIS FLAVIO ET AL: "Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms.", CANCER RESEARCH 1 APR 2005, vol. 65, no. 7, 1 April 2005 (2005-04-01), pages 2906 - 2913, XP002481685, ISSN: 0008-5472 *
MULLER ALEXANDER J ET AL: "Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy", NATURE MEDICINE, vol. 11, no. 3, March 2005 (2005-03-01), pages 312 - 319, XP002481687, ISSN: 1078-8956 *
MUNN ET AL: "Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 18, no. 2, 1 April 2006 (2006-04-01), pages 220 - 225, XP005321333, ISSN: 0952-7915 *
ZHENG XIUFEN ET AL: "Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 OCT 2006, vol. 177, no. 8, 15 October 2006 (2006-10-15), pages 5639 - 5646, XP002481686, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
GB0624308D0 (en) 2007-01-17
WO2008068621A2 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
WO2008068621A3 (en) Combination product with ido inhibitor and tumor targeted ifn-gamma
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
MX349787B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor.
WO2008030883A3 (en) Treatment of cancer
WO2007011962A3 (en) Treatment of cancer
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2008000915A (en) Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof.
MX2009010066A (en) Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer.
UA103614C2 (en) Medicinal composition for treating hepatic cancer which comprises a kinase inhibitor. combined with glypican 3 antibody
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
WO2007090194A3 (en) Lymphatic zip codes in tumors and pre-malignant lesions
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2011054837A3 (en) Bifunctional prodrugs and drugs
WO2008039994A3 (en) Targeted photodynamic therapy agent
EP1991248A4 (en) Antidepressant prodrugs
AU310232S (en) Impact bracket
WO2008082646A3 (en) Histone deacetylase inhibitors, combination therapies and methods of use
MX2010010876A (en) Substituted piperidines as therapeutic compounds.
WO2008006082A3 (en) Energy enhancing formulation
AP2010005435A0 (en) 1,4-Naphthoquinone derivatives and therapeutic usethereof.
AU2010298020A8 (en) Combination
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
WO2007050405A3 (en) The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
MY146803A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859330

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07859330

Country of ref document: EP

Kind code of ref document: A2